Cassie's questions to Ionis Pharmaceuticals Inc (IONS) leadership • Q1 2025
Question
Cassie, on for Luca Issi, asked about the TTR cardiomyopathy market, questioning if Ionis was surprised by a competitor not lowering price after a label expansion and whether WAINUA would compete on price.
Answer
Chief Global Product Strategy Officer Kyle Jenne responded that he was not surprised by the competitor's pricing strategy, suggesting it was likely to balance their existing patient mix. He clarified that the pricing strategy for WAINUA is ultimately partner AstraZeneca's decision and will be based on market dynamics and the drug's value proposition.